Other mechanisms include activation of alternative signaling pathways (such as the MET pathway or the HER2 pathway), histological transformation (from NSCLC to SCLC), and acquisition of genetic alterations in downstream signaling molecules (such as KRAS or PIK3CA). Here, KRAS is linked to small cell lung carcinoma.